Ranbaxy’s Generic version of BMS patented drug
Delhi High Courts rejected US based Parma major BMS (Bristol-Myers Squibb) appeal to ban India’s Ranbaxy Laboratories’ from launching generic version of Hepatitis –B drug named ‘Entecavir’. According to Indian patent law, the patent holders have 20 years of exclusive rights of marketing and impede competitors to launch low cost generic drug markets. ‘Entecavir’ [...]





